Publications by authors named "Fevzi Altuntas"

Claim this Profile
A
A Large Room for Improvement in the Management of Relapsed/Refractory Large B-Cell Lymphoma in Türkiye: Real-World Outcomes in a Setting Without Access to T-Cell Redirecting Therapies.
Umut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, Elif Birtaş Ateşoğlu, Fatma Keklik Karadağ

Turk J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues.
C Andrew Stewart, Shaji Daniel, Elizabeth J Curvino, Yi Zhang, Hafsa Kamboh, Fevzi Altuntas

Nat Biomed Eng· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.
Muhit Özcan, Ryan D Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Fevzi Altuntas

Ther Adv Med Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cholesterol Levels Are Not Associated with Peripheral Blood Stem Cell Mobilization in Healthy Donors.
Sema Seçilmiş, Burcu Aslan Candır, Ersin Bozan, Samet Yaman, Bahar Uncu Ulu

J Clin Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.
Muhit Özcan, Ryan D Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Fevzi Altuntas

Haematologica· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of second allogeneic hematopoietic stem cell transplantation as salvage therapy for hematologic diseases after a first allogeneic transplantation.
Hikmetullah Batgi, Tuğba Zorlu, Mehmet Ali Erkurt, Ant Uzay, Ipek Yonal Hindilerden, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements and challenges in hematopoietic cell mobilization and transplantation: Insights from recent research.
Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomes.
Burcu Aslan Candir, Nazik Okumus, Ipek Yonal Hindilerden, Mehmet Ali Erkurt, Sinem Namdaroglu, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fresh and cryopreserved stem cell transplantation in myeloma patients: Does it make a difference to transplant outcomes?
Mehmet Ali Erkurt, Seda Yilmaz, Sinem Namdaroglu, Sinan Demircioglu, Ahmet Sarici, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of heparin in autologous stem cell mobilization in patients with multiple myeloma.
Ahmet Sarici, Mehmet Ali Erkurt, Seda Yilmaz, Sinan Demircioglu, Ilhami Berber, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biographies of the guest editors for this issue's theme papers on stem cell mobilization and transplantation from a Turkish perspective.
Fevzi Altuntas, Turgay Ulas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does body mass index affect stem cell yield in healthy donors?
Seda Yilmaz, Nazik Okumus, Mert Seyhan, Rasim Sahin, Gulten Korkmaz, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma.
Abdullah Karakus, Ugur Hatipoglu, Yavuz Katircilar, Mehmet Ali Erkurt, Seda Yilmaz, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a relationship between stem cell yield obtained from healthy donors and healthy donors' blood type?
Yavuz Katircilar, Abdulkadir Sahin, Muruvvet Seda Aydin, Kerim Erer, Mehmet Ali Erkurt, Fevzi Altuntas

Transfus Apher Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma.
Tugba Zorlu, Merve Apaydin Kayer, Nazik Okumus, Turgay Ulaş, Mehmet Sinan Dal, Fevzi Altuntas

Diagnostics (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias.
Abdullah Karakus, Tayfur Toptas, Mehmet Sinan Dal, Ali Durdu, Ugur Hatipoglu, Fevzi Altuntas

Bone Marrow Transplant· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç

Br J Haematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solitary Plasmacytomas: Current Status in 2025.
Uğur Hatipoğlu, Mert Seyhan, Turgay Ulas, Mehmet Sinan Dal, Fevzi Altuntaş

Hematol Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ruxolitinib in the management of chronic GVHD.
Asli Odabasi Giden, Mehmet Ali Erkurt, Ipek Yonal Hindilerden, Emine Hidayet, Ilhami Berber, Fevzi Altuntas

Transfus Apher Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a relationship between vitamin D levels and graft versus host disease?
Tugce Nur Yigenoglu, Bahar Uncu Ulu, Sinem Namdaroglu, Mehmet Ali Erkurt, Rasim Sahin, Fevzi Altuntas

Transfus Apher Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?
Tugce Nur Yigenoglu, Mehmet Ali Erkurt, Simten Dagdas, Bahar Uncu Ulu, Irfan Kuku, Fevzi Altuntas

Transfus Apher Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of ruxolitinib in the management of acute GVHD.
Sinem Namdaroglu, Emine Hidayet, Muruvvet Seda Aydin, Mehmet Ali Erkurt, Ilhami Berber, Fevzi Altuntas

Transfus Apher Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are mesenchymal stem cells still effective in acute GvHD management?
Bahar Uncu Ulu, Ipek Yonal Hindilerden, Tugce Nur Yigenoglu, Tarik Onur Tiryaki, Mehmet Ali Erkurt, Fevzi Altuntas

Transfus Apher Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging trends and controversies in GVHD management: Bridging research and clinical practice.
Fevzi Altuntas

Transfus Apher Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization.
Mehmet Bakırtaş, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Semih Başcı, Ali Kılınç

Hematol Transfus Cell Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis